## **Hepatitis C Treatment Plan**

| Patient's Name:  | DOB:                        |
|--|-----------------------------|
| Genotype (including subtype):  |                             |
| Medications: Please indicate drugs, dose a   | nd duration                 |
| (Take or use medication as directed, do no   | t skip a dose)              |
| <ul> <li>□ Sovaldi (sofosbuvir) 400 mg- Take once d</li> <li>□ Olysio (simeprevir) 150 mg- Take once da</li> </ul>   |                             |
| □ <b>Ribavirin mg-</b> Take in the mo  | orning and in the afternoon |
| □ <b>Peginterferon alfa</b> mcg- Inject once   | weekly for weeks            |
| Laboratory Testing- Indicate week during week HCV levels must be obtained at treatment week during wee |                             |
| Week 4-  | (please insert due date)    |
| Week 12  | (please insert due date)    |
| Week 24 (if indicated) -   | (please insert due date)    |
| SVR upon completion of therapy   | (please insert due date)    |

| HCV Genotype and Comorbidities  | Treatment  | Duration   |
|---|--|--|
| Patients with genotype 1 HCV  | sofosbuvir + peginterferon alfa + ribavirin <b>OR</b><br>simeprevir + peginterferon alfa + ribavirin | 12 weeks <b>OR</b> 12 weeks of simeprevir and 24 to 48 weeks of peginterferon alfa + ribavirin |
| Patients with genotype 1 HCV and interferon ineligible                | sofosbuvir + ribavirin   | 24 weeks   |
| Patients with genotype 2 HCV  | sofosbuvir + ribavirin   | 12 weeks   |
| Patients with genotype 3 HCV  | sofosbuvir + ribavirin   | 24 weeks   |
| Patients with genotype 4 HCV  | sofosbuvir + peginterferon alfa + ribavirin  | 12 weeks   |
| Patients with hepatocellular carcinoma awaiting liver transplantation | sofosbuvir + ribavirin   | 48 weeks (or until the time of liver transplantation; whichever occurs first)                  |